A Message From Louis J. DeGennaro, Ph.D.
Interim President and CEO of The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) wants to bring you the most up-to-date blood cancer information. We know how important it is for you to understand your treatment and support options. With this knowledge, you can work with members of your healthcare team to move forward with the hope of remission and recovery.

Our vision is that one day most people who have been diagnosed with acute lymphoblastic leukemia (ALL) will be cured or they will be able to manage their disease with good quality of life. We hope that the information in this Guide will help you along your journey.

LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, advocacy and patient services. Since its first funding in 1954, LLS has invested almost $1 billion in research specifically targeting blood cancers. We will continue to invest in research for cures and in programs and services that improve the quality of life of people who have ALL and their families.

We wish you well.

Louis J. DeGennaro, Ph.D.
Interim President and CEO
Inside This Guide

2   Introduction

3   Here to Help

7   Part 1—Understanding ALL
    About Marrow, Blood and Blood Cells
    About ALL
    Diagnosis

12  Part 2—Treatment
    Choosing a Specialist
    Ask Your Doctor
    Treatment Planning
    About ALL Treatments
    Central Nervous System (CNS) Leukemia
    Postremission Therapy
    Ph-Positive ALL
    Relapsed and Refractory ALL
    Stem Cell Transplantation
    ALL Treatment in Young Adults
    ALL Treatment in Adults

25  Part 3—About Clinical Trials

26  Part 4—Side Effects and Follow-Up Care
    Side Effects of ALL Treatment
    Long-Term and Late Effects
    Follow-Up Care
    Tracking Your ALL Tests

31  Take Care of Yourself

32  Medical Terms

This LLS Guide about ALL is for information only. LLS does not give medical advice or provide medical services.
Introduction

Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Other names for ALL are “acute lymphocytic leukemia” and “acute lymphoid leukemia.” ALL is the most common type of leukemia in children.

Advances in the treatment of ALL have resulted in improved remission rates. The number of patients who have gone into remission or have been cured increases each year.

- About 6,070 people in the United Stated were expected to be diagnosed with ALL in 2013.
- About 66,030 people in the United States are living with or are in remission from ALL as of 2013.

You can view, print or order the free LLS booklet *Acute Lymphoblastic Leukemia* at www.LLS.org/publications. Or, contact our Information Specialists for a copy.
Here to Help

This Guide will help when you talk to your doctor about tests and treatment. Your healthcare team will answer your questions and give support and any needed referrals. Ask your doctor for a professional healthcare interpreter who speaks your native language or uses sign language. Many times, this is a free service.

The news that you have ALL may be a shock to you and your loved ones. You may feel sad, depressed or afraid. Keep in mind that

- The number of patients who have gone into remission is increasing each year.
- New treatments are being studied in clinical trials for patients
  - Of all ages
  - In all stages of treatment.

**LLS Has Ways to Help.** Treatment for ALL will affect your daily life for a period of time. You may want to ask friends or family members to help you

- Get information
- Take care of chores.

LLS offers free information and services for patients and families touched by blood cancers.

**Information Specialists.** Our Information Specialists are master’s level oncology social workers, nurses and health educators. They provide up-to-date information about blood cancers. You can call to speak with an Information Specialist Monday through Friday, 9 a.m. to 9 p.m. ET at (800) 955-4572. You can also send an email to infocenter@LLS.org or chat online at www.LLS.org/informationspecialists.

**Clinical Trials.** Our Information Specialists help patients work with their doctors to find out about specific clinical trials. You can also use our online clinical-trial search service supported by LLS. It offers
patients and caregivers immediate access to listings of blood cancer clinical trials. You can reach this online service by visiting www.LLS.org/clinicaltrials.

**Advocacy and Public Policy.** The LLS Office of Public Policy (OPP) enlists volunteers to help advocate for policies and laws to speed the development of new treatments and improve access to quality medical care. Visit www.LLS.org/advocacy to find out more or get involved.

**Co-Pay Assistance Program.** This program offers assistance for financially eligible patients with certain blood cancer diagnoses to help pay for private or public health insurance premiums and/or co-pay costs for prescription medications. Check www.LLS.org/copay or call (877) 557-2672 to speak to a Co-Pay Assistance Program specialist for eligibility information.

**Language Services.** Free language services are available for calls with our Information Specialists.

**Free Materials and Información en Español.** LLS has free patient education and support booklets in English and Spanish. You can order these materials by phone at (800) 955-4572. You can also read or print the booklets, or order free print versions, at www.LLS.org/publications.

**Chapter Programs and Services.** LLS chapter offices around the United States and Canada offer support and education. Your chapter can arrange for you to speak to another person living with ALL through the *Patti Robinson Kaufmann First Connection Program*. Find your chapter by calling (800) 955-4572 or by visiting www.LLS.org/chapterfind.

**Telephone/Online Education Programs.** LLS provides free telephone and online education programs presented by experts for patients and caregivers. For more information contact our Information Specialists or visit www.LLS.org/programs.

**Children’s Concerns.** Every family that has a member with a diagnosis of ALL becomes a part of an unfamiliar world of treatment and follow-up care. One way to help children feel better about the changes in their lives is to have them take part in “normal” activities as soon as the doctor says it is okay. Parents of a child with ALL may want to talk to members of their child’s healthcare team about how to
find enough time for everything, pay for treatment and best help their children. For more information, see the free LLS booklet *Coping With Childhood Leukemia and Lymphoma.*

**The Trish Greene Back to School Program for Children With Cancer.** This program helps doctors, nurses, parents and school personnel work together for a smooth return to school for children with cancer. For more information, contact your LLS chapter or call (800) 955-4572.

**Reach Out.** You and your loved ones can reach out to others for support. For example

- LLS offers online Blood Cancer Discussion Boards and live online chats at www.LLS.org/getinfo.
- Local or Internet support groups and blogs can give support.
- You may get to know other people living with cancer. These friendships provide support.

**Suggestions From Other People Living With Cancer**

- Get information about choosing a cancer specialist or treatment center.
- Talk with family and friends about how you feel and how they can help you.
- Find out what your insurance covers.
- Find out if financial assistance is available.
- Learn about the most current tests and treatments for ALL.
- Talk openly with your doctor about your fears or concerns.
- Tell your doctor if you have any side effects of treatment.
- Contact your doctor if you have fatigue, fever, pain or sleep problems.
- Get medical advice if you have changes in mood or feelings of sadness or depression.
Information for World Trade Center Responders. People who were involved in the aftermath of the attacks of September 11, 2001, may be eligible for help from the World Trade Center Health Program. These include: responders, workers and volunteers who helped with rescue, recovery and cleanup at the World Trade Center and related sites in New York City; survivors who were in the New York City disaster area, lived, worked, or were in school in the area; and responders to the Pentagon and the Shanksville, PA crashes who have been diagnosed with a blood cancer. For more information, call the World Trade Center Health Program at (888) 982-4748 or visit www.cdc.gov/wtc/faq.html.

We'd Like to Hear From You. We hope this Guide helps you. Please tell us what you think at www.LLS.org/publicationfeedback. Click on LLS Disease & Treatment Publications—Survey for Patients, Family and Friends.
Part 1

Understanding ALL

Leukemia is the general term for a number of different types of blood cancer. ALL is one of four main types of leukemia.

About Marrow, Blood and Blood Cells

The general descriptions below may help you understand the leukemia information in the rest of this Guide.

Marrow is the spongy center inside of bones where blood cells are made.

Blood cells are made in the bone marrow. They begin as stem cells. Stem cells become red blood cells, white blood cells and platelets in the marrow. Then the red blood cells, white blood cells and platelets enter the blood.

Platelets form plugs that help stop bleeding at the site of an injury.

Red blood cells carry oxygen around the body. When the number of red blood cells is below normal, the condition is called anemia. Anemia may make you feel tired or short of breath. It may make the skin look pale.

White blood cells fight infection in the body. There are two major types of white blood cells: germ-eating cells (neutrophils and monocytes) and infection-fighting lymphocytes (B cells, T cells and natural killer [NK] cells).

Plasma is the liquid part of the blood. It is mostly water. It also has some vitamins, minerals, proteins, hormones and other natural chemicals in it.
Normal Blood Cell Count Fast Facts

The ranges of blood cell counts below are for adults. They may be a little different from lab to lab and for children and teens.

**Red blood cell (RBC) count**
- Men: 4.5 to 6 million red cells per microliter of blood
- Women: 4 to 5 million red cells per microliter of blood

**Hematocrit (the part of the blood made up of red cells)**
- Men: 42% to 50%
- Women: 36% to 45%

**Hemoglobin (amount of the red-cell pigment that carries oxygen)**
- Men: 14 to 17 grams per 100 milliliters of blood
- Women: 12 to 15 grams per 100 milliliters of blood

**Platelet count**
- 150,000 to 450,000 platelets per microliter of blood

**White blood cell (WBC) count**
- 4,500 to 11,000 white cells per microliter of blood

**Differential (also called diff)**
- Shows the part of the blood made up of different types of white cells
- The types of white cells counted are neutrophils, lymphocytes, monocytes, eosinophils and basophils.
- Adults usually have about 60% neutrophils, 30% lymphocytes, 5% monocytes, 4% eosinophils and less than 1% basophils in their blood.
About ALL

ALL is a type of cancer that begins in the bone marrow. A person can get ALL at any age. The overall risk of getting ALL is small for children and adults. However, ALL remains the most common type of cancer in children under age 15. The risk of getting adult ALL increases in people age 50 and older.

Causes of ALL. ALL starts with a change to a single cell in the bone marrow. Doctors do not know what causes most cases of ALL. There is no way to prevent ALL. You can’t catch ALL from someone else.

Signs and Symptoms. Many ALL signs and symptoms are also caused by other types of illness. Most people with these signs and symptoms do not have ALL.

A sign is a change in the body that the doctor sees in an exam or a test result.

A symptom is a change in the body that the patient can see or feel.

A person with ALL may have

- Aches in legs, arms or hips
- Black-and-blue marks for no clear reason
- Enlarged lymph nodes
- Fever without obvious cause
- Pale-looking skin
- Pinhead-sized red spots under the skin called petechiae
- Prolonged bleeding from minor cuts
- Shortness of breath during physical activity
- Tiredness or no energy
- Vomiting
- Unexplained weight loss.
Diagnosis

It is important for patients to receive the right diagnosis. ALL is diagnosed with blood and bone marrow tests.

**Blood Cell Counts.** The doctor orders a test called a **CBC** (complete blood count). This test counts the numbers of red blood cells, white blood cells and platelets. Usually, patients with ALL have lower-than-expected red blood cells and platelets.

**Blood Cell Examination.** The cells are stained (dyed) and looked at through a microscope. This test is called a blood smear. A person with ALL usually has too many leukemic blast cells in the blood. Blast cells do not function like normal cells. The blood smear sample can also be used for cytogenetic analysis and immunophenotyping, explained below.

- **Cytogenetic analysis** — Each cell in the body has chromosomes that carry genes. Genes give the instructions that tell each cell what to do. The test called cytogenetic analysis examines the chromosomes of the ALL blast cells.

- **Immunophenotyping** — The test called immunophenotyping shows if the ALL cells are B cells or T cells. Most people have B-cell ALL.

**Bone Marrow Tests.** Other tests will be done to make sure the diagnosis of ALL is correct. Tests called **bone marrow aspiration** and **bone marrow biopsy** are done. These tests take a close look at the ALL cells. They also find out the percentage of ALL cells in the bone marrow.

The doctor uses information from all of the tests to decide

- The type of drug therapy a patient needs
- How long treatment will last.

The type and length of treatment may also depend on the patient’s age.
How are the Blood and Bone Marrow Tests Done?

**Blood Test** — a small amount of blood is taken from the patient’s arm with a needle. The blood is collected in tubes and sent to a lab.

**Bone Marrow Aspiration** — a sample of cells is taken from the marrow.

**Bone Marrow Biopsy** — a very small amount of bone filled with marrow cells is taken from the body.

Both bone marrow tests are done with a special needle. Some patients are awake for the procedure. They get medication first to numb the part of the body that will be used to get the sample of cells. Some patients are given a drug that makes them sleep during this procedure. The sample of cells is usually taken from the patient’s hip bone.

Blood and marrow tests may be done in the doctor’s office or in a hospital. A bone marrow aspiration and biopsy are almost always done at the same visit.

Blood and marrow tests are also done during and after treatment. The tests are repeated to see if treatment is destroying the ALL cells.

*Want more information?* You can view, print or order the free LLS booklet *Understanding Lab and Imaging Tests* at www.LLS.org/publications. Or, contact our Information Specialists for a copy.
Treatment

Choosing a Specialist

Choose a doctor who specializes in treating ALL. He or she should know about the most up-to-date treatments. This type of specialist is usually called a hematologist-oncologist. Or, your local cancer specialist can work with a leukemia specialist.

Ways to Find an ALL Specialist

- Ask your primary care doctor.
- Contact your community cancer center.
- Call your local medical society.
- Reach out to doctor and/or health plan referral services.
- Call our Information Specialists.
- Use online doctor-finder resources, such as
  - The American Medical Association’s (AMA) “DoctorFinder.”
  - The American Society of Hematology’s (ASH) “Find a Hematologist.”

Want more information? You can view, print or order the free LLS fact sheet *Choosing a Blood Cancer Specialist or Treatment Center* at www.LLS.org/publications. Or, contact our Information Specialists for a copy.
Ask Your Doctor

Talk with the doctor and ask questions about how he or she plans to treat your ALL. This will help you to

- Be actively involved in your care
- Make decisions.

This Guide includes questions to ask your doctor about ALL treatment (see the inside back cover).

It may be helpful to write down the answers to your questions and review them later. You may want to have a caregiver, family member or friend with you when you talk to your doctor. This person can listen, take notes and offer support. Some people like to audio record information from the doctor and then listen to the recording later on.

People with ALL who are unsure about their treatment options are encouraged to get a second opinion.

Want more information? For a list of Healthcare Question Guides about second opinions and other topics that you can print, go to www.LLS.org/whattotalk. Or, contact our Information Specialists for copies.

Treatment Planning

There are three stages of treatment for ALL

- Induction therapy
- Consolidation therapy (also called “intensification”)
- Maintenance therapy.

Consolidation and maintenance are postremission therapies. These are described beginning on page 19.
The goal of treatment for ALL is to cure the disease.

- Many children with ALL are cured.
- The number of adults with ALL in remission (no sign of the disease) has increased.
- The length of remission in adults has improved.

Many children with ALL are treated in clinical trials. Adults with ALL should talk to their doctors about clinical trials. A clinical trial may be a good treatment choice for you or your child. Clinical trials are explained beginning on page 25.

Some things that may affect the outcome of your ALL treatment are

- Your subtype of ALL
- The results of your lab tests
- Your age and general health
- Your medical history, including whether you were treated before with chemotherapy
- Whether you have
  - A serious infection at the time of diagnosis
  - ALL in your central nervous system
  - ALL that has not responded to treatment or has relapsed.

The bone marrow examination gives the doctor important information for treatment planning.

**Pretreatment Considerations.** Infertility is a concern for adults of childbearing age and parents of children diagnosed with ALL. Ask the doctor for information that may lessen the risk for infertility.

You can view, print or order the free LLS fact sheet *Fertility* at www.LLS.org/publications. Or, contact our Information Specialists for a copy.
About ALL Treatments

Treatment for patients with ALL (or relapsed ALL) may include

- Chemotherapy
- Stem cell transplantation
- New approaches under study (called clinical trials).

A patient may receive different drugs from those described in this Guide. This may still be considered proper treatment.

Speak to your doctor to find out what treatment is best for you.

Our Information Specialists can help you plan questions to ask your doctor about treatment.

**Induction Therapy.** Induction therapy is the first round of treatment with chemotherapy. Most ALL patients need to start induction chemotherapy right away. Induction therapy is done in the hospital.

Patients are often in the hospital for four to six weeks.

The aims of induction therapy are to

- Kill as many ALL cells as possible
- Get blood counts back to normal
- Get rid of all signs of the disease for an extended period of time.

### Names of Some Induction Therapy Drugs for ALL

- Daunorubicin (Cerubidine®) or doxorubicin (Adriamycin®) by central line, port or PICC
- Asparaginase *Erwinia chrysanthemi* (Erwinaze®) or pegaspargase (PEG-L asparaginase; Oncaspar®) by injection
- Vincristine (Oncovin®) by central line, port or PICC
- Dexamethasone or prednisone (corticosteroids) by mouth
- Methotrexate by injection into the spinal fluid
- Cytarabine (cytosine arabinoside, ara-C, Cytosar-U®) by injection into the spinal fluid
Chemotherapy and other drugs. Chemotherapy and some other types of drugs kill or damage cancer cells. Several types of drugs are used to kill ALL cells. Each drug type works in a different way. Combining the drugs can make the treatment work better.

The first round of chemotherapy usually does not get rid of all the ALL cells. Most patients will need more rounds of treatment. Usually the same drugs are used for the added rounds.

Some drugs are given by mouth. Other drugs are given through a central line, port or PICC. Central lines, ports or PICCs can be used to give medications, nutrition and blood cells. They can be used to take blood samples, too. Central lines, ports and PICCs can stay in place for weeks or months. Talk to your doctor about the best one for you or your child to use.

Central Lines, Ports and PICCs

**Central Line** — A thin tube that is put under the skin and into a large vein in the chest. The central line stays firmly in place. “Catheter” is another word for central line.

**Port** — This is a small device that is used with a central line. The port is placed under the skin of the chest. After the site heals, no dressings and no special home care are needed. The doctor or nurse can give medicines or nutrition or take blood samples. He or she puts a needle through the skin into the port. A numbing cream can be put on the skin before the port is used.

**PICC or PIC Line** (short for “percutaneously inserted central venous catheter”) — A PICC is inserted through a vein in the arm.
# Some ALL Drugs

These are some of the standard ALL drugs used. Some drugs under study in ALL clinical trials are also listed.

<table>
<thead>
<tr>
<th>Drug Types</th>
<th>Drug Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimetabolites</td>
<td>clofarabine (Clolar®), cytarabine (cytosine arabinoside; ara-C, Cytosar-U®), 6-mercaptopurine (Purinethol®), methotrexate, 6-thioguanine (Tabloid®), nelaarabine (Arranon®)</td>
</tr>
<tr>
<td>Antitumor Antibiotics</td>
<td>daunorubicin (Cerubidine®), doxorubicin (Adriamycin®), mitoxantrone (Novantrone®), idarubicin (Idamycin®)</td>
</tr>
<tr>
<td>DNA Repair Enzyme Inhibitor</td>
<td>etoposide (VP-16; VePesid®)</td>
</tr>
<tr>
<td>DNA-Damaging Agent</td>
<td>cyclophosphamide (Cytoxan®)</td>
</tr>
<tr>
<td>Drugs That Prevent Cells from Dividing</td>
<td>vincristine (Oncovin®), liposomal vincristine (Marqibo®)</td>
</tr>
<tr>
<td>Enzymes That Prevent Cells From Surviving</td>
<td>asparaginase <em>Erwinia chrysanthemi</em> (Erwinaze®), pegaspargase (PEG-L-asparaginase; Oncaspar®)</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td>imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), ponatinib (Iclusig®)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>prednisone, prednisolone, dexamethasone</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>alemtuzumab (Campath®), rituximab (Rituxan®)</td>
</tr>
</tbody>
</table>

Information about side effects begins on page 26.
Central Nervous System (CNS) Leukemia

Patients may have ALL cells in the lining of the spinal cord and brain. A spinal tap (also called a lumbar puncture) is used to check the spinal fluid for ALL cells. Every ALL patient gets treatment to prevent CNS leukemia. Even if ALL cells are not found in the spinal fluid, patients are still treated.

The spinal cord and brain are hard to reach with chemotherapy that is given through a vein in the arm. So, spinal fluid is removed and chemotherapy is injected right into the spinal canal. Drugs such as methotrexate, cytarabine and hydrocortisone are used.

Radiation therapy may be given to the spine or brain. Sometimes both chemotherapy (methotrexate, cytarabine and hydrocortisone) and radiation therapy are used. In some practices, doctors are not using cranial radiation for pediatric patients. Cranial radiation will be used in cases of T-cell ALL and in patients who have a CNS relapse. When radiation therapy is not used, the chance of long-term effects decreases.

Spinal taps are done from time to time throughout treatment. This test checks to see if the ALL cells are being killed.
Postremission Therapy

When there is no sign of ALL, this is called a remission. Unfortunately, more treatment is usually needed even after an ALL patient is in remission. Some ALL cells may remain. These are not found by common blood or marrow tests. This part of ALL treatment is called postremission therapy. (Postremission means after remission.) Chemotherapy is used in postremission therapy for ALL. Stem cell transplantation may be part of postremission therapy for some ALL patients. Postremission therapy consists of consolidation (intensification) therapy and maintenance therapy.

- Consolidation therapy is usually given in cycles for four to six months.
- Maintenance therapy is usually given for about two years.

For most people, the drugs used during consolidation and maintenance therapy are different than the drugs used during induction therapy.

The doctor considers many things when deciding a treatment plan. This includes ALL subtype, doses and length of consolidation and maintenance therapy. The doctor also asks

- Did the induction therapy kill the ALL cells?
- Does the patient have changes to the chromosomes of the ALL cells?

Some types of ALL are usually treated with higher doses of drugs during induction, consolidation and maintenance therapy. These types include T-cell ALL, ALL in infants and ALL in adults.

An allogeneic stem cell transplant may be a good treatment for some ALL patients. Allogeneic transplants are explained beginning on page 22.
Some Consolidation and Maintenance Therapies

- Vincristine (Oncovin®) by intravenous (IV) infusion
- Prednisone or dexamethasone by mouth
- Mercaptopurine (Purinethol®) by mouth
- Methotrexate by mouth, IV or injection into the spinal fluid
- Cytarabine (cytosine arabinoside, ara-C, Cytosar-U®) by IV or injection into the spinal fluid
- Asparaginase *Erwinia chrysanthemi* (Erwinaze®) or PEG-L asparaginase (Oncaspar®) by injection
- Cyclophosphamide (Cytoxan®) by intravenous (IV) infusion
- Doxorubicin (Adriamycin®) by intravenous (IV) infusion
- Thioguanine (Tabloid®) by mouth
- Hydrocortisone by injection into the spinal fluid
- Radiation therapy to the head and sometimes to the spine

Ph-Positive ALL

About one out of five adults with ALL has a type called Ph-positive ALL. A small number of children (two to four out of 100 children) with ALL have Ph-positive ALL.

**Induction Therapy.** Ph-positive ALL may be treated with imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®) or ponatinib (Iclusig™). Other chemotherapy drugs will be used as well. Gleevec, Sprycel, Tasigna and Iclusig are given by mouth.

**Postremission Therapy.** During consolidation and maintenance therapy, Gleevec, Sprycel, Tasigna or Iclusig is given with other drugs. Usually people with Ph-positive ALL stay on Gleevec, Sprycel, Tasigna or Iclusig after maintenance chemotherapy is completed.
**Relapsed and Refractory ALL**

Most children with ALL are cured of their disease. Some patients have a remission after treatment, but then ALL cells return later (called **relapsed ALL**). Patients may have ALL cells in the marrow even after treatment (called **refractory ALL**).

Patients with relapsed ALL may be

- Treated with the same drugs as newly diagnosed patients
- Given different drugs
- Given an allogeneic stem cell transplant if they have a matched donor. Information about allogeneic transplantation begins on page 22.

With refractory ALL

- Drugs that were not used in the first round of treatment may be given
- An allogeneic stem cell transplant may also be a part of treatment.

For children with relapsed or refractory ALL

- The drug clofarabine (Clolar®) is approved by the FDA to treat children (from age 1 to 21) if the usual treatments do not work.
- Treatment with Clolar followed by an allogeneic transplant may result in a cure.

A stem cell transplant is usually not considered for a child unless

- Doctors have determined that the child’s type of ALL is not likely to respond well to chemotherapy
- Chemotherapy has not worked well
- The ALL has returned (relapsed).

Liposomal vincristine (Marqibo®) is approved for adult patients with Ph chromosome-negative ALL who have relapsed two or more times. It is also approved for patients whose leukemia has progressed following two or more regimens of therapy.
Another drug, nelarabine (Arranon®), is approved for patients with relapsed T-cell ALL.

**Stem Cell Transplantation**

Your doctor will talk with you about whether stem cell transplantation is a treatment option for you. Information about different types of transplants is on the next pages.

**Allogeneic Stem Cell Transplantation.** An allogeneic transplant uses stem cells from a donor. The donor may be a brother or sister. Or the donor can be an unrelated person. This person’s stem cells “match” the patient’s. Stem cells may also come from a cord blood unit (the blood in the umbilical cord after a baby’s birth). The goals of an allogeneic transplant are to

- Restore the body’s ability to make normal blood cells after high-dose chemotherapy
- Cure the patient of his or her ALL by killing any remaining ALL cells.

Allogeneic transplants may be done in the hospital. First, the patient is given high-dose chemotherapy and/or radiation therapy. Stem cells are collected from a donor. The donor stem cells are given to the patient through an intravenous (IV) line or central line. The donor stem cells go from the patient’s blood to the bone marrow. They help start a new supply of red blood cells, white blood cells and platelets.

An allogeneic transplant is a high-risk procedure. Doctors are working to make allogeneic transplants safer. An allogeneic transplant may be a choice for an adult ALL patient if

- He or she is not doing well with other treatments
- The expected benefits of an allogeneic transplant exceed the risks
- There is a stem cell donor.
The upper age limit for an allogeneic transplant depends on the treatment center.

A reduced-intensity allogeneic transplant uses lower doses of chemotherapy than a standard allogeneic transplant. Some older and sicker patients may be helped by this treatment. Many centers use 70 years as the upper age limit for a reduced-intensity allogeneic transplant. Your doctor will talk to you about whether a reduced-intensity allogeneic transplant is a treatment option for you.

A reduced-intensity allogeneic transplant may be a choice for an ALL patient if

- He or she is not doing well with other treatments
- A standard allogeneic transplant is not a choice because of the patient’s age or overall health
- The expected benefits of a reduced-intensity allogeneic transplant exceed the risks
- There is a stem cell donor.

**Autologous Stem Cell Transplantation.** An autologous transplant uses the patient’s own stem cells.

Your doctor will talk with you about whether an autologous transplant is a treatment option for you. It is not commonly used to treat ALL. This is because of the high relapse rate following this type of transplant.

Want more information? You can view, print or order the free LLS publications *Blood and Marrow Stem Cell Transplantation* and *Cord Blood Stem Cell Transplantation* at www.LLS.org/publications. Or, contact our Information Specialists for a copy.
ALL Treatment in Young Adults

Older adolescents and adults younger than 40 are often called young adults. Traditionally, treatment for this group has been similar to adult treatment protocols. However, a number of cancer centers are using pediatric protocols to treat young adult patients. Speak to your doctor or call an Information Specialist about the different clinical trials that may be available to you.

ALL Treatment in Adults

The risk of developing ALL peaks at age four. Then it decreases until about age 50. At age 50, the incidence increases again, especially among men.

Today, cures are possible for some adults with ALL. These include those who may have other serious health problems. But treatment results in adults are not as good as treatment results in children. ALL in adults is more resistant to treatment than ALL in children. New and better treatments for ALL in adults are needed.

A number of cancer centers are using pediatric protocols to treat younger adult patients. Talk to your doctor about the treatment options available to you.
Part 3

About Clinical Trials

There are new treatments under study for ALL patients of all ages.

New treatments are studied in clinical trials. Clinical trials are also used to study new uses for approved drugs or treatments. For example, changing the amount of the drug might be more effective. Or, giving the drug along with another type of treatment might work better. Some clinical trials combine drugs for ALL in new sequences or dosages.

There are clinical trials for

- Newly diagnosed ALL patients
- Patients who do not have a good response to treatment
- Patients who relapse after treatment.

A carefully conducted clinical trial may provide the best available therapy.

Ask your doctor if treatment in a clinical trial is right for you. Drugs being studied in clinical trials are listed in the chart on page 17. You can call our Information Specialists for information about clinical trials. Or, you can use our free clinical-trial search service at www.LLS.org/clinicaltrials.

Want more information? You can view, print or order the free LLS publications Understanding Clinical Trials for Blood Cancers and Knowing All Your Treatment Options at www.LLS.org/publications. Or, contact our Information Specialists for copies.
Side Effects and Follow-Up Care

Side Effects of ALL Treatment

The term side effect describes the way that treatment affects healthy cells.

The aim of treatment for ALL is to kill the ALL cells. Treatment for ALL also affects healthy cells. Side effects of ALL treatment may be severe, but they usually go away once treatment ends. Ask your doctor about the side effects to expect from your treatment.

ALL treatment may affect your blood cell counts.

- The number of red blood cells may decrease (anemia). Red blood cell transfusions (red blood cells that are donated and given to the patient) may be needed to increase red blood cell counts.

- Patients may also have a drop in the number of platelets. A platelet transfusion may be needed to prevent bleeding if a patient’s platelet count is very low.

- A big drop in the number of white blood cells may lead to an infection. These infections are usually treated with antibiotics. Fever or chills may be the only signs or symptoms of infection.

Patients with an infection may also have

- Coughing

- Sore throat

- Pain when urinating

- Frequent loose bowel movements.

Growth factors are sometimes given to increase white blood cells.
G-CSF (Neupogen® and Neulasta®) and GM-CSF (Leukine®) are drugs that increase the number of white blood cells.

Growth factors are only given to children in certain cases. Scientists are studying which children with ALL are most likely to be helped by treatment with growth factors to prevent infection.

To lower the risk of infection

- The patient, the patient’s visitors and the medical staff need to wash their hands often and well.
- The patient’s central line must be kept clean.
- Patients should take good care of their teeth and gums.

The doctor may talk about the absolute neutrophil count, or ANC. This is the number of neutrophils (a type of white blood cell) a person has in his or her body to fight an infection.

**Other Treatment Side Effects.** Chemotherapy affects the parts of the body where new cells form quickly. This includes the inside of the mouth and bowel, and the skin and hair. The side effects listed here are common during chemotherapy

- Mouth sores
- Diarrhea
- Hair loss
- Rashes
- Nausea
- Vomiting.

Not all patients have these side effects. Treatment to prevent or manage nausea, vomiting, diarrhea and other side effects can help patients feel more comfortable.
Chemotherapy may cause the amount of uric acid to increase in the blood of some ALL patients. Some patients also have a buildup of uric acid from the disease itself. Uric acid is a chemical made in the body. A high level of uric acid can cause kidney stones.

Patients with high uric acid levels may be given

- A drug called allopurinol (Aloprim®, Zyloprim®) by mouth
- A drug used called rasburicase (Elitek®), which is given by IV.

Information about long-term and late effects of treatment begins below.

---

**Long-Term and Late Effects**

Long-term effects are medical problems that last for months or years after treatment ends. Fatigue is an example. Late effects are medical problems that do not show up until years after treatment ends. Heart disease is an example.

Not everyone who is treated for ALL develops long-term or late effects. It depends on the patient’s age, overall health and treatment.

Children who are treated for ALL may have

- Growth problems
- Fertility problems (ability to have children later on)
- Bone problems
- Heart problems
- Learning problems.
Adults who are treated for ALL may have
- Fertility problems
- Thyroid problems
- Trouble concentrating
- Persistent fatigue.

Patients should talk with their doctors about
- Any long-term or late effects that may be related to their treatment
- When a child’s learning skills should be checked.

Want more information?
You can view, print or order the free LLS fact sheets *Long Term and Late Effects of Treatment for Childhood Leukemia or Lymphoma* and *Long Term and Late Effects of Treatment in Adults* at www.LLS.org/publications. Or, contact our Information Specialists for copies.

**Follow-Up Care**

Medical follow-up is important for every ALL patient. Follow-up care helps the doctor to see if more treatment is needed. Children and adults should see their primary care doctor for follow-up care. They should also see an oncologist (cancer specialist) for follow-up care. Patients should talk to the doctors about how often to have follow-up visits. They can ask what tests they will need. They can also find out how often to have the tests. It is important for patients to get a record of the cancer treatment they received. This is so their doctors can follow up on specific late effects that may be associated with their treatment.
Follow-up care includes physical exams and blood tests. Sometimes bone marrow tests are also needed. As treatment progresses, the doctor may advise longer periods of time between follow-up visits. This will happen if a patient

- Continues to be free of signs of ALL
- Does not need medical care for any long-term or late effects.

To find a follow-up clinic and other resources for child and adult survivors, contact our Information Specialists.

**Tracking Your ALL Tests**

These tips may help you save time and learn more about your health. Ask your doctor why certain tests are being done and what to expect.

- Discuss test results with your doctor.
- Ask for and keep copies of lab reports in a file folder or binder. Organize the reports in date order.
- Find out if and when follow-up tests are needed.
- Mark upcoming appointments on your calendar.
Take Care of Yourself

- Keep all appointments with the doctor.
- Discuss how you feel with the doctor at each visit. Ask any questions you may have about side effects.
- People with ALL may have more infections than other people. Follow the doctor’s advice for preventing infection.
- Eat healthy foods each day. It is okay to eat four or five smaller meals instead of three bigger ones.
- Contact the doctor about tiredness, fever or other symptoms.
- Do not smoke. Patients who smoke should get help to quit.
- Get enough rest and exercise. Talk with your doctor before starting an exercise program.
- Keep a healthcare file with copies of lab reports and treatment records.
- Have regular cancer screening. See your primary care doctor to keep up with other healthcare needs.
- Talk with family and friends about how you feel. When family and friends know about ALL and its treatment, they may worry less.
- Seek medical advice if you feel sad or depressed and your mood does not improve over time. For example, if you feel sad or depressed every day for a two-week period, seek help. Depression is an illness. It can and should be treated even when a person is being treated for ALL. Treatment for depression has benefits for people living with cancer.
Medical Terms

**Absolute Neutrophil Count (ANC).** The number of neutrophils (a type of white blood cell) that a person’s body has to fight infection.

**Anemia.** A decrease in the level of hemoglobin in the blood.

**Antibiotics.** Drugs that are used to treat infections caused by bacteria or fungi. Penicillin is one type of antibiotic.

**Blast cells.** Early bone marrow cells. About 1 to 5 percent of normal marrow cells are blast cells. In ALL, up to 20 percent of marrow cells may be blast cells.

**Bone marrow aspiration.** A procedure to remove and examine marrow cells to see if they are normal. A liquid sample of cells is taken from the marrow. Then, the cells are looked at under a microscope.

**Bone marrow biopsy.** A procedure to remove and examine marrow cells to see if they are normal. A very small amount of bone filled with marrow cells is taken from the body. Then, the cells are looked at under a microscope.

**Central line.** Special tubing the doctor puts into a large vein in the upper chest. This prepares a patient for chemotherapy treatment. The central line is used to give the patient chemotherapy drugs and blood cells. It also can remove blood samples. Also called indwelling catheter.

**Central nervous system prophylaxis.** Treatment directed to the lining of the spinal cord and brain. ALL cells often collect here.

**Chemotherapy or drug therapy.** Treatment with chemical agents to treat ALL and other cancers.

**Chromosomes.** Any of the 23 pairs of certain basic structures in human cells. Chromosomes are made up of genes. Genes give the instructions that tell each cell what to do. The number or shape of
chromosomes may not be normal in blood cancer cells.

**Clinical trials.** Careful studies done by doctors for new drugs or treatments, or studies done for new uses of approved drugs or treatments. The goal of clinical trials for blood cancers is to improve treatment and quality of life and to find cures.

**Combination chemotherapy or drug therapy.** The use of two or more drugs together to treat ALL and other cancers.

**Consolidation therapy.** Added treatment given to a cancer patient after the disease is in remission. It usually includes chemotherapy drugs not used during induction therapy. Also called **intensification therapy.**

**Cytogenetic analysis.** The examination of the chromosomes of ALL cells. This gives doctors information about how to treat patients. Cell samples can be taken from blood or bone marrow.

**Diagnose.** To detect a disease from a person’s signs, symptoms and test results. The doctor diagnoses a patient.

**FDA.** The short name for the **U.S. Food and Drug Administration.** Part of the FDA’s job is to assure the safety and security of drugs, medical devices and the U.S. food supply.

**FISH.** The short name for **fluorescence in situ hybridization,** a test to measure the presence in cells of a specific chromosome or gene. This test can be used to plan treatment and to measure the results of treatment.

**Hematologist.** A doctor who treats blood cell diseases.

**Hemoglobin.** The part of the red cell that carries oxygen.

**Immune system.** Cells and proteins in the body that defend it against infection.

**Immunophenotyping.** A lab test that can be used to identify the type of ALL cells.
**Induction therapy.** The initial treatment with chemotherapy (or radiation therapy). The aim of induction therapy is to kill a maximum number of blood cancer cells so as to induce a remission (absence of signs or effects of the disease).

**Intensification therapy.** Another name for **consolidation therapy.**

**Leukemia.** A cancer of the marrow and blood.

**Lymph nodes.** Small bean-shaped organs around the body that are part of the body’s immune system.

**Maintenance therapy.** Chemotherapy given to ALL patients after several weeks of induction and consolidation therapy to help destroy the remaining ALL cells. Maintenance therapy is given for about two years.

**Marrow.** The spongy material in the center of bones where blood cells are made.

**Oncologist.** A doctor who treats patients with cancer.

**Pathologist.** A doctor who identifies disease by studying cells and tissues under a microscope.

**PCR.** The short name for **polymerase chain reaction,** a sensitive lab test that can measure the presence of cancer cell-markers in the blood or marrow. PCR is used to detect remaining cancer cells that cannot be detected by other tests.

**Plasma.** The liquid part of the blood.

**Platelet.** A type of blood cell that helps prevent bleeding. Platelets cause plugs to form in the blood vessels at the site of an injury.

**Postremission therapy.** The treatment given to ALL patients after induction therapy. Postremission therapy may have two parts: consolidation (or intensification) and maintenance.

**Radiation therapy.** Treatment with x-rays or other high-energy rays.
Refractory ALL. ALL that has not responded to initial treatment. Refractory disease may be a disease that is getting worse or staying the same even after treatment (stable disease).

Relapse or recurrence. When disease comes back after it has been successfully treated.

Remission. No sign of the disease and/or a period of time when the disease is not causing any health problems.

Signs and symptoms. Changes in the body that show the presence of disease. A sign is a change that the doctor sees in an exam or a lab test result. A symptom is a change that a patient can see or feel.

Stem cell. A type of cell found in bone marrow that makes red blood cells, white blood cells and platelets.
REACH OUT TO OUR INFORMATION SPECIALISTS

The Leukemia & Lymphoma Society’s (LLS) Information Specialists provide patients, families and healthcare professionals with the latest information on leukemia, lymphoma and myeloma. Our team consists of master’s level oncology professionals who are available by phone Monday through Friday, 9 am to 9 pm (ET).

Co-Pay Assistance
LLS’s Co-Pay Assistance Program helps blood cancer patients cover the costs of private and public health insurance premiums, including Medicare and Medicaid, and co-pay obligations. Support for this program is based on the availability of funds by disease. For more information, call 877.557.2672 or visit www.LLS.org/copay.

For a complete directory of our patient services programs, contact us at 800.955.4572 or www.LLS.org (Callers may request a language interpreter.)
Our Mission:


LLS is a nonprofit organization that relies on the generosity of individual, foundation and corporate contributions to advance its mission.